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Abstract: Co-administration of a long-acting B2-agonist and a long acting muscarinic antagonist 
produces superior bronchodilation compared with their individual effects. Our preclinical data 
indicated that combining aclidinium bromide (ACLI) and formoterol fumarate (FORM) provides 
synergistic benefit on smooth muscle relaxation of both large and small human airways. Data 
from more than 2,000 patients in eleven clinical trials documented that ACLI/FORM, a twice-
daily fixed-dose combination, produces a greater degree of bronchodilation than ACLI or 
FORM monotherapy alone and is safe and well tolerated. Two large key trials have shown that 
there is a benefit in using ACLI/FORM when the clinical target is the variability of symptoms 
and mainly nighttime and/or early morning symptoms. ACLI/FORM is the only long acting 
muscarinic antagonist/long acting B2-agonist fixed-dose combination that has been studied for 
this therapeutic indication.
Keywords: aclidinium, formoterol, fixed-dose combination, COPD, symptoms
Background
A solid body of evidence indicates that simultaneous administration of a long-acting 
B2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) produces superior 
bronchodilation compared with their individual effects.1–7 In addition, the examination of 
the literature reveals that the majority of the patients reported outcomes such as dyspnea, 
other symptoms, rescue medication use, and quality of life, improve more with free LABA/
LAMA combinations than with the individual components administered alone.8
Simultaneous stimulation of B2-adrenoceptors and inhibition of the action of 
acetylcholine at muscarinic receptors with antimuscarinic agent may elicit a larger 
bronchodilation by relaxing the airway smooth muscle (ASM) in a more complete 
manner.9 Furthermore, the intracellular crosstalk makes the B2-adrenoceptors and the 
muscarinic pathways so linked to explain the favorable ASM relaxation induced by 
LABA/LAMA combinations.10,11
The disparity in the duration of action of the twice-daily LABAs and a once-daily 
LAMA, and the differences in the devices used to deliver the single medications, render 
these free combinations inconvenient and unpredictable, especially if focused on the 
adherence to prescribed treatment.12,13 Therefore, several fixed-dose combinations 
(FDCs) of once- or twice-daily LABAs and LAMAs in a single delivery device have 
been developed.14
In this review, we will focus on the clinical and functional benefits that can be 
achieved in many COPD patients through the use of the twice-daily aclidinium bromide/
formoterol fumarate (ACLI/FORM) FDC.
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Characteristics of monocomponents
ACLI is a twice-daily LAMA developed for maintenance 
treatment of COPD.15 Preclinical data showed that it has 
an intriguing pharmacodynamic and pharmacokinetic 
profile.15 A recent translation study has compared, in the 
same patients and human tissues, the onset of action of ACLI, 
glycopyrronium, and tiotropium, the three LAMAs currently 
approved for the treatment of COPD.16 Experiments carried 
out in human-isolated bronchi documented a very fast and 
concentration-dependent onset of action for glycopyrronium, 
whereas both ACLI and tiotropium were able to induce 50% 
relaxation of ASM only at the highest concentration admin-
istered in the baths, but ACLI was faster than tiotropium in 
relaxing human-isolated bronchi. In COPD patients, ACLI 
and glycopyrronium elicited a faster onset of action and 
induced a larger bronchodilation in the first 90 minutes of 
inhalation when compared with tiotropium. Key Phase III 
trials documented that ACLI 400 Mg twice-daily shows sig-
nificant improvements in lung function and other important 
patient reported outcomes, such as health-related quality of 
life, dyspnea, and nighttime/early morning symptoms, and is 
safe.15 A recent Cochrane systematic review has shown that, 
in comparison with placebo, ACLI led to an improvement 
in quality of life and a reduction in hospitalizations due to 
severe exacerbations in patients with moderate-to-severe 
stable COPD.17
The well-known pharmacodynamic characteristics of 
FORM make judging this agent as the most suitable LABA 
in a FDC with a twice-daily LAMA. FORM causes a fast 
bronchodilation that arises within a few minutes after inha-
lation, is dose-dependent and not significantly different 
from that caused by salbutamol.18,19 In patients with COPD, 
FORM (12–36 Mg) significantly improves lung function over 
12 hours.20 Moreover, FORM is effective, safe, and well 
tolerated.21 The results of many multicenter clinical trials 
indicate that FORM is an efficacious therapeutic option in 
the treatment of COPD.21
Preclinical development of ACLI/
FORM combination
A preclinical study explored the potential for a pharmacologi-
cal interaction between ACLI and FORM on the relaxation 
of human large and small airways.22
Both ACLI and FORM were able to induce potent, sig-
nificant, and long-lasting relaxation of large airways. Inter-
estingly, the coadministration of low concentrations of these 
drugs caused a reduction in electrical field stimulation- or ace-
tylcholine-induced ASM tone by acting in a synergistic way. 
The electrical field stimulation-induced contractile response 
was inhibited by both ACLI and FORM in a time-dependent 
manner, a confirmation of the long duration of action of 
these compounds. Intriguingly, the synergistic interaction 
elicited by the coadministration of ACLI and FORM allowed 
a noticeably more rapid reduction of the electrical field 
stimulation-induced contraction of ASM, and this relaxant 
effect was sustained for up to 6 hours after administration of 
the drugs. ACLI and FORM were also able to potently relax 
small airways, although FORM, but not ACLI, completely 
relaxed them. Furthermore, the combination was particu-
larly effective at inhibiting the contractile response of small 
airways, with a wider extent of synergistic interaction from 
low-to-high concentrations than in larger airways.
These results suggested that combining ACLI and FORM 
provides synergistic benefit on ASM relaxation of both large 
and small airways and fully supported the clinical develop-
ment of ACLI/FORM FDC.
Clinical development of ACLI/
FORM FDC
Several reviews have already described the clinical develop-
ment of ACLI/FORM FDC.23–27 The common conclusion of 
these reviews, based on efficacy and safety data from more 
than 2,000 patients in eleven clinical trials is that ACLI/
FORM FDC produces a greater degree of bronchodila-
tion than ACLI or FORM monotherapy alone. However, 
the pivotal trials do not allow to establish yet whether this 
benefit translates into improved long-term outcomes of 
decreased exacerbation frequency, improved quality of life, 
and decreased disease-specific mortality, although ACLI/
FORM FDC increases the percentage of patients with an 
improvement in symptoms and health-related quality of life 
compared with monotherapies. The combination appears to 
be safe and well tolerated in clinical trials.
Even with these highlighted shortcomings, Astra 
Zeneca announced on 24 November 2014 that Duaklir® 
Genuair® (ACLI/FORM FDC, 340/12 Mg) was granted 
Marketing Authorization by the European Commission to be 
used as a maintenance bronchodilator treatment for airflow 
obstruction and relief of symptoms in adult patients with 
COPD.28 In fact, the Committee for Medicinal Products for 
Human Use concluded that benefits of ACLI/FORM FDC 
are greater than its risks and recommended its approval for 
use in the European Union.29 However, the Committee for 
Medicinal Products for Human Use remarked that the results 
of clinical trial showed that ACLI/FORM FDC significantly 
improved lung function in patients with COPD compared 
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with placebo, but the improvement was small when ACLI/
FORM FDC was compared with FORM.
Role of ACLI/FORM FDC in COPD 
treatment
The first major difference between ACLI/FORM FDC and 
other FDCs that are already granted Marketing Authorisation 
by the European Commission is that ACLI/FORM FDC is 
the only twice-daily FDC.
It must still be determined whether it is preferable to 
administer a bronchodilator on a once- or twice-daily basis. 
The simplification of the dosing schedule with once-daily 
dosing might increase treatment adherence,30 but we must 
highlight that there are no published data yet to support 
improved adherence or effectiveness with ACLI/FORM FDC 
compared to other LABA/LAMA FDCs. Moreover, dosing 
frequency seems to be of greater importance to pulmonolo-
gists than primary care physicians.31
Beeh and Beier suggested that the longer duration of 
action of once-daily bronchodilators causes not only an 
increase in the net area under the curve time/air flow improve-
ment ratios increases and in morning FEV1 after the last inha-
lation (“through” FEV1) but also on average, less dyspnea, 
and facilitated lung emptying during tidal breathing at rest 
throughout the whole day.32 Duration of effect and dosing 
interval or frequency (eg, once or twice daily) are not neces-
sarily the same, although they are closely interrelated and 
are a function of maintenance dose and pharmacokinetics.33 
Intriguingly, at least in theory, with the same total daily 
dose, a twice-daily regimen provides higher bronchodilation 
at trough than a once-daily regimen according to data from 
a population pharmacodynamic model of the longitudinal 
FEV1 response to ACLI in COPD patients.
34
In any case, the mean changes from baseline in trough 
FEV1 after 6-month treatment were with ACLI/FORM 
400/12 Mg delivered dose 143 mL vs placebo (treatment dif-
ferences: 85 mL vs formoterol 12 Mg, and 26 mL vs ACLI 
400 Mg),35 with glycopyrronium/indacaterol 50/110 Mg 
160 mL (treatment differences: 70 mL vs indacaterol 150 Mg, 
and 90 mL vs glycopyrronium 50 Mg),36 with umeclidinium/
vilanterol 62.5/25 Mg 208–211 mL (treatment differences: 
90 mL vs vilanterol 25 Mg, and 22 mL vs umeclidinium 
125 Mg),37 with tiotropium/olodaterol 5/5 Mg 136 mL (treat-
ment differences: 85 mL vs olodaterol 5 Mg, and 60 mL vs 
tiotropium 5 Mg).38 In the absence of head-to-head compari-
son it is difficult to determine whether the modest differ-
ences between the different FDCs have a real clinical value. 
Rather, observing the values of trough FEV1 generated by 
the different FDCs, it becomes obvious that the question is 
whether the doses of the bronchodilators approved for the 
treatment of COPD are delivered into the lung at isoeffective 
concentrations. We believe that the lack of isoeffectiveness 
explains the differences in bronchorelaxation that have been 
found for different medications belonging to the same class 
of drugs.11
Another important feature of ACLI/FORM FDC is that 
it induces a rapid bronchodilation, within 5 minutes,35 and is 
probably the FDC with the fastest onset of action, considering 
the characteristics of the individual components. A recent 
study has shown that ACLI plus FORM not only induced a 
faster onset of action compared with that produced by mono-
components but also showed a synergistic interaction that 
at 5 minutes postadministration was higher than 50% when 
compared with the expected additive effect and remained 
constant after 2 hours postdose.39
Since it is not yet clear what is the importance of the 
rapidity of bronchodilator onset of action in COPD, no study 
has compared yet the onset of action of different FDCs. 
On repeated dosing, fast onset may not be particularly use-
ful in patients who take their treatment regularly and have 
relatively stable symptoms.33 Conversely, it might be useful 
in patients with suboptimal adherence to treatment, in view 
of the fact that fast-onset bronchodilation would translate into 
fast relief of dyspnea (as in the case of salbutamol used as res-
cue medication) and perceived rapid efficacy could reinforce 
compliance.33 Since there is a significant correlation between 
acute bronchodilator effect and symptom improvement, 
which is strongest in patients with baseline hyperinflation,40 
it has been hypothesized that fast onset of action could also 
be useful in patients with more variable symptoms.33
There is solid evidence now that patients with COPD 
experience symptoms all throughout the day.40 However, 
the perception of the magnitude of symptoms by patients 
varies over the course of the day and even over the course 
of the week.41 The majority of patients with COPD suffer 
from symptoms at night.42,43 Many patients also suffer from 
bothersome symptoms early in the morning.41,44,45 Those with 
either or both of the symptoms at night or symptoms in early 
morning are associated with poorer health status compared to 
those without.46 Patients with COPD expect their treatment to 
provide fast symptom relief, greater mobility, and improve-
ment in morning activities.47 Improved disease management 
may reduce nighttime/early morning symptoms and improve 
health status in patients with COPD.46
Despite the described evidence of variation in perceived 
symptoms during the day and the documentation that diurnal 
International Journal of COPD 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4
Matera et al
dyspnea is a good predictor of mortality in stable COPD 
patients,48 this appears to be hardly considered in actual 
treatment plans. Apparently, patients with more variable 
symptoms tend to be more likely to adapt their treatment in 
response to worsening symptoms.41 This is definitely not the 
best approach to possibly reduce the variability of symptoms. 
Consequently, there is a need to provide health care profes-
sionals with treatment strategies able to lessen the impact 
of this variation.48
The ACLI formoterol-COPD (ACLI FORM-COPD) key 
study, a 24-week double-blind, parallel-group, active- and 
placebo-controlled, multicenter Phase III study, conducted 
at 193 centers in Europe and South Africa, also explored 
the effects on symptoms of two doses of ACLI/FORM FDC 
(400/12 and 400/6 Mg) vs the monotherapy components 
(ACLI 400 Mg and FORM 12 Mg) and placebo (Table 1).35 
The total Exacerbations of COPD Tool-Respiratory Symp-
toms (EXACT-RS) scale, a patient-reported outcome mea-
sure designed to evaluate respiratory symptoms in clinical 
trials, and the nighttime and early morning symptoms scores, 
were used to explore changes from baseline in COPD symp-
toms. The EXACT-RS utilizes eleven respiratory symptom 
items from the existing and validated 14-item EXACT, 
which measures symptoms of exacerbation, and is a reliable, 
valid, and responsive measure of respiratory symptoms of 
COPD suitable for use in natural history studies and clinical 
trials.49 Nighttime/early morning symptoms were assessed 
using a 14-item Nighttime and Early Morning Symptoms 
questionnaire completed every morning. The psychometric 
qualities of the Nighttime and Early Morning Symptoms 
questionnaires have been evaluated and final instruments 
developed.50,51 Higher EXACT-RS, nighttime and early 
morning symptoms scores indicated more severe symptoms. 
The improvements in EXACT-RS with both ACLI/FORM 
FDC doses were significantly larger compared with the 
single agents. Both doses of ACLI/FORM FDC significantly 
improved overall nighttime symptom severity score vs 
placebo and monotherapies, with the exception of the FDC 
400/12 Mg dose vs FORM 12 Mg. Changes from baseline 
in early morning symptoms scores with both ACLI/FORM 
FDC doses achieved statistical significance compared with 
placebo and ACLI monotherapy, whereas only FDC 400/6 Mg 
significantly improved early morning symptoms scores vs 
FORM. Compared with placebo, both ACLI/FORM FDCs 
significantly improved Transition Dyspnea Index focal score 
above the minimum clinically important difference of 1 unit 
at week 24 and at all other time points. Both ACLI/FORM 
FDCs also showed numerically greater improvements vs T
ab
le
 1
 P
ha
se
 II
I p
iv
ot
al
 s
tu
di
es
St
ud
y
D
es
ig
n
N
um
be
r 
 
of
 p
at
ie
nt
s
T
re
at
m
en
ts
R
es
ul
ts
Si
ng
h 
et
 a
l35
24
-w
ee
k 
do
ub
le
-
bl
in
d,
 p
ar
al
le
l-
gr
ou
p,
 a
ct
iv
e-
 a
nd
 
pl
ac
eb
o-
co
nt
ro
lle
d,
 
m
ul
tic
en
te
r 
st
ud
y
1,
72
9
T
w
ic
e-
da
ily
 A
C
LI
/
FO
R
M
 F
D
C
 
40
0/
12
 M
g 
or
 
40
0/
6 
Mg
, A
C
LI
 
40
0 
Mg
, F
O
R
M
 1
2 
Mg
 
or
 p
la
ce
bo
Si
gn
iﬁ
ca
nt
 im
pr
ov
em
en
t 
w
ith
 A
C
LI
/F
O
R
M
 F
D
C
 4
00
/1
2 
Mg
 a
nd
 4
00
/6
 M
g 
in
 1
 h
ou
r 
po
st
do
se
 F
EV
1 v
s 
A
C
LI
 (
12
5 
an
d 
69
 m
L,
 
re
sp
ec
tiv
el
y)
, t
ro
ug
h 
FE
V
1 v
s 
FO
R
M
 (
85
 a
nd
 5
3 
m
L)
 a
nd
 T
D
I f
oc
al
 s
co
re
 v
s 
pl
ac
eb
o 
(1
.2
9 
an
d 
1.
16
 u
ni
ts
)
N
o 
st
at
is
tic
al
ly
 s
ig
ni
ﬁc
an
t 
di
ffe
re
nc
es
 b
et
w
ee
n 
ac
tiv
e 
an
d 
pl
ac
eb
o 
tr
ea
tm
en
ts
 in
 S
G
R
Q
 t
ot
al
 s
co
re
, b
ut
 a
 s
ig
ni
ﬁc
an
tly
 h
ig
he
r 
pr
op
or
tio
n 
of
 p
at
ie
nt
s 
re
ce
iv
in
g 
A
C
LI
/F
O
R
M
 F
D
C
 4
00
/6
 M
g 
w
ith
 
4 
un
its
 d
ec
re
as
e 
in
 S
G
R
Q
 t
ot
al
 s
co
re
 a
t 
w
ee
k 
24
 v
s 
pl
ac
eb
o
A
C
LI
/F
O
R
M
 F
D
C
 4
00
/1
2 
st
at
is
tic
al
ly
 s
up
er
io
r 
to
 t
he
 A
C
LI
/F
O
R
M
 F
D
C
 4
00
/6
 M
g 
in
 1
 h
ou
r 
po
st
do
se
 F
EV
1
Im
pr
ov
em
en
t 
nu
m
er
ic
al
ly
 g
re
at
er
 in
 t
ro
ug
h 
FE
V
1 w
ith
 A
C
LI
/F
O
R
M
 F
D
C
 4
00
 v
s 
A
C
LI
D
’U
rz
o 
et
 a
l52
24
-w
ee
k 
do
ub
le
-
bl
in
d,
 p
ar
al
le
l-
gr
ou
p,
 a
ct
iv
e-
 a
nd
 
pl
ac
eb
o-
co
nt
ro
lle
d,
 
m
ul
tic
en
te
r 
st
ud
y
1,
69
2
T
w
ic
e-
da
ily
 A
C
LI
/
FO
R
M
 F
D
C
 4
00
/1
2 
or
 4
00
/6
 M
g,
 A
C
LI
 
40
0 
Mg
, F
O
R
M
 1
2 
Mg
 
or
 p
la
ce
bo
Si
gn
iﬁ
ca
nt
 im
pr
ov
em
en
t 
w
ith
 A
C
LI
/F
O
R
M
 F
D
C
 4
00
/1
2 
an
d 
40
0/
6 
Mg
 in
 1
 h
ou
r 
po
st
do
se
 F
EV
1 v
s 
A
C
LI
 (
10
8 
an
d 
87
 m
L,
 
re
sp
ec
tiv
el
y)
, a
nd
 w
ith
 A
C
LI
/F
O
R
M
 F
D
C
 4
00
/1
2 
in
 t
ro
ug
h 
FE
V
1 v
s 
FO
R
M
 (
45
 m
L)
N
um
er
ic
al
ly
 g
re
at
er
 im
pr
ov
em
en
t 
w
ith
 A
C
LI
/F
O
R
M
 F
D
C
 4
00
/6
 M
g 
in
 t
ro
ug
h 
FE
V
1 v
s 
FO
R
M
 (
26
 m
L)
N
um
er
ic
al
ly
 g
re
at
er
 im
pr
ov
em
en
t 
in
 t
ro
ug
h 
FE
V
1 w
ith
 A
C
LI
/F
O
R
M
 F
D
C
 4
00
/1
2 
vs
 4
00
/6
 M
g
Si
gn
iﬁ
ca
nt
 im
pr
ov
em
en
t 
w
ith
 A
C
LI
/F
O
R
M
 F
D
C
 4
00
/1
2 
in
 T
D
I f
oc
al
 s
co
re
 v
s 
FO
R
M
N
um
er
ic
al
ly
 g
re
at
er
 im
pr
ov
em
en
ts
 in
 T
D
I f
oc
al
 s
co
re
s 
co
m
pa
re
d 
to
 e
ith
er
 m
on
ot
he
ra
py
 w
ith
 A
C
LI
/F
O
R
M
 F
D
C
 4
00
/1
2 
an
d 
40
0/
6 
Mg
Im
pr
ov
em
en
ts
 in
 T
D
I f
oc
al
 s
co
re
s 
si
m
ila
r 
be
tw
ee
n 
A
C
LI
/F
O
R
M
 F
D
C
 4
00
/1
2 
an
d 
40
0/
6 
Mg
Si
gn
iﬁ
ca
nt
 im
pr
ov
em
en
ts
 in
 S
G
R
Q
 t
ot
al
 s
co
re
s 
w
ith
 t
he
 A
C
LI
/F
O
R
M
 F
D
C
s 
an
d 
th
e 
m
on
ot
he
ra
pi
es
 v
s 
pl
ac
eb
o
M
ea
n 
di
ffe
re
nc
es
 in
 S
G
R
Q
 t
ot
al
 s
co
re
 o
ve
r 
pl
ac
eb
o 
ex
ce
ed
ed
 t
he
 M
C
ID
 o
f 4
 u
ni
ts
 in
 p
at
ie
nt
s 
tr
ea
te
d 
w
ith
 A
C
LI
/F
O
R
M
 F
D
C
 
40
0/
12
 M
g 
or
 A
C
LI
 m
on
ot
he
ra
py
A
bb
re
vi
at
io
ns
: A
C
LI
, a
cl
id
in
iu
m
 b
ro
m
id
e;
 F
EV
1,
 fo
rc
ed
 e
xp
ir
at
or
y 
vo
lu
m
e 
in
 1
 s
; F
D
C
, ﬁ
xe
d-
do
se
 c
om
bi
na
tio
n;
 F
O
R
M
, f
or
m
ot
er
ol
 fu
m
ar
at
e;
 M
C
ID
, m
in
im
um
 c
lin
ic
al
ly
 im
po
rt
an
t d
iff
er
en
ce
; S
G
R
Q
, S
t G
eo
rg
e’
s 
R
es
pi
ra
to
ry
 Q
ue
st
io
nn
ai
re
; 
T
D
I, 
T
ra
ns
iti
on
 D
ys
pn
ea
 In
de
x.
International Journal of COPD 2015:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5
Aclidinium: formoterol FDC in COPD
monotherapies. More patients treated with a FDC rather 
than either placebo or monotherapies achieved the minimum 
clinically important difference.
A second Phase III study, the ACLI/FORM combination 
for investiGative use in the treatMENT of moderate-to-severe 
COPD, conducted in 222 centers throughout North America, 
Australia, and New Zealand, replicated the same protocol 
(Table 1).52 The changes from baseline in overall average 
daily EXACT-RS scores were numerically improved for 
ACLI/FORM FDC 400/12 Mg and significantly improved 
for ACLI/FORM FDC 400/6 Mg vs either single agent. 
Patients in the ACLI/FORM FDC treatment groups reported 
greater reduction in overall nighttime COPD symptom 
severity vs placebo and either monotherapy at week 24, 
which was statistically significant for ACLI/FORM FDC 
400/6 Mg vs ACLI. At week 24, both ACLI/FORM FDCs 
significantly improved the average rating for overall early 
morning COPD symptom severity vs placebo and ACLI, 
but not vs FORM. Interestingly, the 28-week ACLI/FORM 
combination for investiGative use in the treatMENT trial 
extension for patients in the US and Canada documented that 
improvements in Transition Dyspnea Index focal score were 
numerically greater with ACLI/FORM (both doses) than with 
either constituent bronchodilator at all visits up to week 5253 
and, even more important if focused on symptoms control, 
average daily rescue medication use over the course of the 
study was reduced compared with baseline.54
Data from these two large trials suggest that there is 
a benefit in using ACLI/FORM when our clinical target 
is the variability of symptoms, although the signal is not 
really very strong. In particular, the small difference in 
the impact on early morning COPD symptoms compared 
to monotherapy with FORM leaves us perplexed also 
because it contrasts with the documented faster and larger 
bronchodilation that is obtained when ACLI and FORM 
are coadministered compared to that elicited by the two 
single components.39 However, currently ACLI/FORM 
is the only LAMA/LABA FDC that has been studied for 
this therapeutic indication. In any case, the availability of 
a treatment that is able to control the variability of symp-
toms and mainly to reduce nighttime and/or early morning 
symptoms is extremely important. In fact, COPD patients 
with nighttime and/or early morning symptoms have lower 
health-related quality of life, while those with both report 
greater work productivity loss and greater activity impair-
ment vs patients with no symptoms.46 Improved disease 
management may lower the economic impact on patients, 
employers, and the health care system.
In our opinion, ACLI/FORM FDC must be considered a 
useful, validated approach at least to the symptomatic treat-
ment of COPD. We completely agree that better control of 
symptoms in the morning could benefit the patient throughout 
the day, leading to fewer periods of worsening symptoms 
and, in the longer term, fewer exacerbations.45 Roche et al45 
have suggested that the chronic bronchitic phenotype might 
be the one that could take more advantage from a targeted 
treatment on symptoms.
Obviously, we cannot exclude that also other LAMA/
LABA FDCs, which are all once-daily FDCs, might be able to 
control the variability of COPD symptoms, mainly nighttime/
early morning symptoms. Unfortunately, there is still a lack of 
clear documentation that this is the case. Therefore, we are still 
waiting for a specifically designed trial that will allow us to 
establish whether twice-daily administration may be preferred 
to the once-daily dosing of bronchodilators mainly when 
twice-daily administration is administered in the evening or 
early in the morning. Regrettably, the wide availability of 
LAMA/LABA FDCs in the absence of head-to-head compara-
tive pragmatic trials definitely makes difficult and, in any case, 
empiric, the choice of the combination to be used. Moreover, 
it is likely that these trials will not be carried out, both for their 
cost and the lack of interest that the pharmaceutical companies 
have to produce potential data that might be unfavorable to 
them. In any case, we believe that also any overlap between 
the chronic bronchitic phenotype and the putative “morning 
symptoms phenotype” as well as the impact of ACLI/FORM 
on this specific phenotype warrant further research.
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